Search

Viatris Inc

Slēgts

SektorsVeselības aprūpe

20.83 0.73

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

20.73

Max

20.86

Galvenie mērījumi

By Trading Economics

Ienākumi

-207M

-325M

Pārdošana

-7.3M

3.7B

EPS

0.71

Dividenžu ienesīgums

2.41

Peļņas marža

-8.676

Darbinieki

30,000

EBITDA

209M

938M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+0.86% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

2.41%

1.98%

Nākamais dividenžu datums

2026. g. 16. dec.

Nākamais Ex dividenžu datums

2026. g. 23. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2B

23B

Iepriekšējā atvēršanas cena

20.1

Iepriekšējā slēgšanas cena

20.83

Viatris Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. nov. 20:46 UTC

Viatris Inc. is trading higher, having fluctuated earlier in the session, and is positioned above its 20-day moving average near the upper end of its one-month range.

2026. g. 12. nov. 23:11 UTC

Viatris Inc. is trading higher in after-market hours, reaching its highest point of the day and positioned above its 20-day moving average.

2026. g. 11. nov. 21:06 UTC

News

Viatris Inc. will participate in three upcoming investor conferences, including the UBS Global Biopharma Conference on November 17.

2026. g. 9. nov. 21:04 UTC

Viatris Inc. is moving higher, supported by rising U.S. wholesale inventories and cautious optimism from Federal Reserve officials ahead of key inflation data.

2026. g. 7. nov. 00:01 UTC

Viatris Inc. is trading lower in after-market hours, showing a slight decline while remaining above its 20-day moving average and near the upper end of its one-month range.

2026. g. 6. nov. 23:01 UTC

In after-market trading, Viatris Inc. is roughly flat compared to Friday's close, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. g. 5. nov. 21:04 UTC

News

Viatris reports Q3 adjusted EPS of $0.71, exceeding estimates, but posts a net loss of $325.3 million and revenue of $3.75 billion, below expectations.

2026. g. 4. nov. 22:02 UTC

Viatris Inc. is trading higher in after-market hours, advancing alongside the broader market and remaining well above its 20-day moving average.

2026. g. 3. nov. 22:02 UTC

Viatris Inc. shares declined in after-market trading, remaining stable above their 20-day moving average and near the upper end of their one-month range.

2026. g. 2. nov. 21:09 UTC

Viatris Inc. shares fell as the broader market declined, dropping from an initial gain to the day's lowest point since Friday's close.

2026. g. 30. okt. 19:36 UTC

News

Viatris initiates cash tender offer to acquire Pacira BioSciences at $36.50 per share, with unanimous board support; offer expires November 16, 2026.

2026. g. 29. okt. 23:41 UTC

Viatris Inc. is declining in after-market trading, having retraced from a peak earlier in the session and nearing its lowest point of the day.

2026. g. 28. okt. 20:07 UTC

Viatris Inc. shares advanced, reaching a peak reflecting nearly 1% cumulative return earlier in the session, while overall trading activity remained routine.

2026. g. 27. okt. 22:41 UTC

Viatris Inc. is trading modestly lower in after-market hours, having retraced from a brief high earlier in the session.

2026. g. 26. okt. 20:06 UTC

News

Piper Sandler raises price target on Viatris Inc to $14.00 from $13.00 while maintaining a Neutral rating, published today at 8:02 AM ET.

2026. g. 23. okt. 20:13 UTC

Viatris Inc. is trading modestly higher in after-market hours, maintaining a steady position above its 20-day moving average since Friday's close.

2026. g. 21. okt. 19:36 UTC

News

JPMorgan raises Viatris price target to $20.00 from $18.00 while maintaining a Neutral rating, amid cautious sentiment contributing to today's decline.

2026. g. 20. okt. 20:51 UTC

Viatris Inc shares fell during after-market trading, continuing a downward trend since Tuesday's close despite a brief recovery earlier in the session.

2026. g. 19. okt. 20:13 UTC

Viatris Inc. shares advanced modestly during after-market hours, maintaining a cumulative return since the close of regular trading and positioned above its 20-day moving average.

2026. g. 16. okt. 23:01 UTC

News

Viatris receives FDA approval for Ryzumvi to treat presbyopia in adults and seeks U.S. partners for commercialization under a licensing agreement with Opus Genetics.

2026. g. 15. okt. 20:02 UTC

News

Barclays issues a bullish outlook on Viatris, citing a positive setup for Q3 and optimism for fiscal year 2027.

2026. g. 14. okt. 20:07 UTC

Viatris Inc shares are advancing, building on gains since Tuesday, despite pulling back from an earlier session high. The stock is trading around its one-month range midpoint.

2026. g. 13. okt. 19:36 UTC

Viatris Inc shares fell, continuing a downward trend that began after Monday's close, despite an initial peak in early trading.

2026. g. 12. okt. 20:06 UTC

Viatris Inc shares fell modestly, reflecting a broader market trend, while fluctuating around the midpoint of their one-month range.

2026. g. 9. okt. 23:50 UTC

In after-market trading, Viatris Inc shares advanced, reflecting upward momentum and reaching a high cumulative return since Friday's close.

2026. g. 8. okt. 20:13 UTC

Event

Viatris Inc announces acquisition of Pacira BioSciences for $1.65 billion, including all remaining shares not tendered in the initial offer.

2026. g. 7. okt. 20:08 UTC

Social Media

Viatris Inc shares are declining as the FDA review of its MR-141 drug approaches on October 17, despite earlier gains in the session.

2026. g. 6. okt. 20:06 UTC

Viatris Inc shares fell modestly, retracing after an initial rise and closing below Monday's close, while remaining above the 20-day moving average.

2026. g. 5. okt. 20:06 UTC

Viatris Inc's shares are trading roughly flat, with little change since Friday's close, remaining around the middle of its one-month trading range.

2026. g. 2. okt. 23:45 UTC

Viatris Inc declined in after-market hours, continuing a trend of lower prices observed over the past four sessions since Friday's close.

Salīdzinājums

Cenas izmaiņa

Viatris Inc Prognoze

Cenas mērķis

By TipRanks

0.86% augšup

Prognoze 12 mēnešiem

Vidējais 21 USD  0.86%

Augstākais 28 USD

Zemākais 14 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Viatris Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

9 ratings

5

Pirkt

3

Turēt

1

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
help-icon Live chat